Trials / Completed
CompletedNCT02926456
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta®): the STart Of REzolsta (ST.O.RE.) Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 337 (actual)
- Sponsor
- Janssen-Cilag S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the effectiveness of darunavir/cobicistat (DRV/c)-based regimens, measured as maintenance of virological suppression 48 weeks after baseline, defined as the day when the treatment with DRV/c-based regimen is started, through collection of daily practice data in the Italian setting.
Conditions
Timeline
- Start date
- 2016-07-22
- Primary completion
- 2018-02-14
- Completion
- 2018-02-14
- First posted
- 2016-10-06
- Last updated
- 2018-04-24
Source: ClinicalTrials.gov record NCT02926456. Inclusion in this directory is not an endorsement.